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Abstract
Background:  Parkinson's disease (PD) is the most common neurodegenerative movement
disorder, characterized clinically by resting tremor, bradykinesia, postural instability and rigidity.
The prevalence of PD is approximately 2% of the population over 65 years of age and 1.7 million
PD patients (age ≥ 55 years) live in China. Recently, a common LRRK2 variant Gly2385Arg was
reported in ethnic Chinese PD population in Taiwan. We analyzed the frequency of this variant in
our independent PD case-control population of Han Chinese from Taiwan.
Methods:  305 patients and 176 genetically unrelated healthy controls were examined by
neurologists and the diagnosis of PD was based on the published criteria. The region of interest
was amplified with standard polymerase chain reaction (PCR). PCR fragments then were directly
sequenced in both forward and reverse directions. Differences in genotype frequencies between
groups were assessed by the X2 test, while X2 analysis was used to test for the Hardy-Weinberg
equilibrium.
Results: Of the 305 patients screened we identified 27 (9%) with heterozygous G2385R variant.
This mutation was only found in 1 (0.5%) in our healthy control samples (odds ratio = 16.99, 95%
CI: 2.29 to 126.21, p = 0.0002). Sequencing of the entire open reading frame of LRRK2 in G2385R
carriers revealed no other variants.
Conclusion: These data suggest that the G2385R variant contributes significantly to the etiology
of PD in ethnic Han Chinese individuals. With consideration of the enormous and expanding aging
Chinese population in mainland China and in Taiwan, this variant is probably the most common
known genetic factor for PD worldwide.
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Background
Parkinson's disease (PD) is the most common neurode-
generative movement disorder, characterized clinically by
resting tremor, bradykinesia, postural instability and
rigidity. The prevalence of PD is approximately 2% of the
population over 65 years of age and 1.7 million PD
patients (age ≥ 55 years) live in China [1,2]. Mutations in
five genes have been shown to cause parkinsonism: α-
synuclein (dominant), parkin (recessive), DJ-1  (reces-
sive), PINK1 (recessive) and LRRK2 (dominant) [3]. Since
LRRK2 mutation has been reported as a cause of PD, a
number of LRRK2 substitutions have been identified to be
pathogenic [4]. To date, the most common genetic variant
underlying sporadic PD is the G2019S variant reported at
up to 40% frequencies in different Caucasian populations
[5]. The genotype-phenotype correlations have been stud-
ies on this mutation [6]. The clinical manifestations of the
G2019S carriers closely resemble those of typical PD with
pleomorphic pathological findings [7,8]. The rarity of the
G2019S mutation in Chinese population suggests the
occurrence of this mutation resulted from a common
European founder [9]. Recently, a common variant
Gly2385Arg was reported in ethnic Chinese PD popula-
tion in Taiwan [10,11]. In this study, we analyzed the fre-
quency of this variant in our independent PD case-control
population of Han Chinese from Taiwan and explore the
genotype-phenotype correlations of this prevalent altera-
tion in our Taiwanese PD cohort.
Methods
Subjects
305 patients with sporadic idiopathic PD (46% Female,
Mean age of onset: 61.8 ± 10.6 years, Range: 30–91 years)
were selected from the neurology clinic of Chang-Gung
Memorial Hospital. 176 unrelated healthy adult volun-
teers (46% female, Mean Age at exam: 59.6 ± 9.6 years,
Range: 38–86 years) were matched for ethnic origin and
area of residence. These normal control individuals are
genetically unrelated to the individuals in the patient
group. All patients were examined by a neurologist (YR
Wu or CM Chen), and the diagnosis of PD was based on
the published criteria [12]. Patients with evidence of sec-
ondary parkinsonism or with atypical features such as
early dementia, ophthalmoplegia, early autonomic fail-
ure, and pyramidal signs were not included in this study.
All examinations were performed after obtaining
informed consent under a protocol approved by the inter-
nal ethics and scientific boards of National Institutes of
Health.
Genotyping and statistical analysis
Genomic DNA was extracted from peripheral blood using
standard protocols. The region of interest was polymerase
chain reaction (PCR)-amplified as previously described.
Assay of the G7153A polymorphism in all the individuals
was performed by PCR amplification with primer pair 5'-
ATGCAGCTTTCAGTGATTCCA-3' (forward) and 5'-TCT-
GAAAAGATGGTGCTGAGAAG-3' (reverse). Cycle
sequencing in forward and reverse directions was per-
formed on purified PCR products with the Big Dye Termi-
nator chemistry and run on an ABI 3100 automated DNA
sequencer. (Applied Biosystems, Foster City, CA). Differ-
ences in genotype frequencies between groups were
assessed by the X2 test. X2 analysis was used to test for the
Hardy-Weinberg equilibrium (HWE).
Results
Of the 305 patients screened we identified 27 (9%) with
heterozygous for the G2385R variant. This mutation was
only found in 1 (0.5%) in our healthy control samples
(odds ratio = 16.99, 95% CI: 2.29 to 126.21, p = 0.0002).
In both groups, there were no deviations from HWE at
this G7153A locus. None of the patients with the 2385R
variant had a family history of PD. Age of onset for the
2385R carriers was 33–79 years (mean 61.5 ± 11.3 years).
Meanwhile, age of onset of 285 PD cases without the
2385R variant was 31–91 years (mean 61.9 ± 10.5 years).
Sequencing of the entire open reading frame and flanking
intronic sequence (>50 bp) of LRRK2 in 2385R carriers
revealed no other coding variants.
The clinical presentations of all G2385R carriers showed
no difference from typical idiopathic PD with definite
asymmetric onset, bradykinesia, resting tremor (4–6 Hz),
rigidity (Table 1). All carriers showed response to
dopamine replacement therapy based on clinical observa-
tion.
Discussion
LRRK2, encodes a protein called dardarin that is postu-
lated as a member of the ROCO protein family. There are
five conserved domains in this protein. The LRRK2 kinase
domain belongs to the MAPKKK subfamily of kinases. The
active sites of all kinases are located in a cleft between an
N-terminal and a C-terminal lobe, typically covered by an
activation loop in an inactive confirmation. The residue
G2385 substitution lies in the WD40 domain. WD40
domain is speculated to be capable of of mediating pro-
tein-protein interactions [13]. Hypothetically, LRRK2
G2385R variant may cause a conformational change of
the WD40 domain of LRRK2. The functional effects of the
G2385R substitution on dardarin have yet to be estab-
lished.
The lack of the G2385 variant in other populations, except
ethnic Chinese PD populations, highlights the fact that
the contribution of different genetic factors varies
amongst different populations [11]. Furthermore, these
discrepancies between mutation frequencies across differ-
ent ethnicities worldwide lend support to the hypothesisBMC Neurology 2006, 6:47 http://www.biomedcentral.com/1471-2377/6/47
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of a founder effect. Our findings delineate LRRK2-related
disease as a common form of sporadic PD in the Chinese
population.
Based on our results, the G2385R variant contributes sig-
nificantly to the etiology of PD in ethnic Han Chinese
individuals. With consideration of the enormous and
expanding aging Chinese population in mainland China
and in Taiwan, this genetic variant is probably the most
common known genetic risk factor for PD worldwide. A
routine testing for this mutation at least in our population
may be cost-effective. Though whether our finding
extends to other Asian populations needs further verifica-
tion. Complete analysis of the entire 51 exons of LRRK2
will be warranted before recommendations and guide-
lines for screening of LRRK2 in other ethnic PD patients
for diagnostic purposes and genetic counselling be imple-
mented globally.
Conclusion
In conclusion, our data suggest that the G2385R variant
contributes significantly to the etiology of PD in ethnic
Han Chinese individuals. With consideration of the enor-
mous and expanding aging Chinese population in main-
land China and in Taiwan, this variant is probably the
most common known genetic factor for PD worldwide.
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Table 1: Comparison of clinical manifestations between PD 2385R carriers and PD non 2385 carriers
PD (2385R Carrier) PD(Non 2385R Carrier)
Number of subject 27 278
Age of Onset(Mean ± SD) 61.5 ± 11.3 61.9 ± 10.5
Resting tremor (n, %) 26(96) 252 (88)
Bradykinesis (n, %) 27(100) 269 (97)
Rigidity (n, %) 26(96) 261(94)
Asymmetrical onset (n, %) 20(74) 203(73)
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